The fourth JAK inhibitor ‘Cibinqo ‘ has landed at general hospitals in Korea.

According to industry sources, Pfizer Korea’s new Janus kinases (JAK) inhibitor ‘Cibinqo (abrocitinib)’ passed the drug committees (DCs) of various medical institutions in Korea, including the Seoul National University Hospital.

The drug, which is approved for atopic dermatitis, is Pfizer’s follow-up of ‘Xeljanz (tofacitinib)’ that is set to compete with ‘’ Lilly Korea’s ‘Olumiant (baricitinib),’ ‘Abbvie’s ‘Rinvoq (upadacitinib)' for the same indication.

Olumiant and Rinvoq were approved for reimbursement in May this year, and the reimbursement listing process for Cibinqo is also